| 2.65 0 (0%) | 01-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.1 | 1-year : | 3.62 |
| Resists | First : | 2.66 | Second : | 3.1 |
| Pivot price | 2.58  |
|||
| Supports | First : | 2.34 |
Second : | 2.15 |
| MAs | MA(5) : | 2.62 |
MA(20) : | 2.58 |
| MA(100) : | 2.06 |
MA(250) : | 1.63 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 97.6 |
D(3) : | 91.2 |
| RSI | RSI(14): 73.2 | |||
| 52-week | High : | 2.66 | Low : | 0.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RPTX ] has closed below upper band by 6.2%. Bollinger Bands are 58.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.65 - 2.67 | 2.67 - 2.68 |
| Low: | 2.62 - 2.63 | 2.63 - 2.64 |
| Close: | 2.63 - 2.65 | 2.65 - 2.67 |
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Fri, 30 Jan 2026
Shay Capital LLC's Strategic Acquisition of Repare Therapeutics Inc Shares - GuruFocus
Thu, 29 Jan 2026
Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 125.3% in January - MarketBeat
Wed, 28 Jan 2026
Repare Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Mon, 19 Jan 2026
Repare Shareholders Approve Acquisition by XenoTherapeutics - citybiz
Fri, 16 Jan 2026
Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics - TipRanks
Fri, 16 Jan 2026
RPTX - Repare Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 64.1 (%) |
| Shares Short | 438 (K) |
| Shares Short P.Month | 352 (K) |
| EPS | -1.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.68 |
| Profit Margin | 0 % |
| Operating Margin | -3.8 % |
| Return on Assets (ttm) | -29.8 % |
| Return on Equity (ttm) | -49.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.11 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -1.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -70 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -1.56 |
| PEG Ratio | 0 |
| Price to Book value | 0.98 |
| Price to Sales | 9.62 |
| Price to Cash Flow | -1.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|